Compare ClearPoint Neuro Inc (CLPT) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Cognizant Technology Solutions Corp — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M), while Cognizant Technology Solutions Corp trades at $43.1 (market cap $20.34B). The key difference: Cognizant Technology Solutions Corp is far larger — about 42.5× ClearPoint Neuro Inc's market cap, and Cognizant Technology Solutions Corp pays a 3.07% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | CTSH | |
|---|---|---|
Market Cap | $478.63M | $20.34B |
Sector | Health | Technology |
52-Week High | $29.60 | $86.70 |
52-Week Low | $8.66 | $38.73 |
Enterprise Value | $506.63M | $19.92B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Cognizant (CTSH) trades at $44.16, up 3.74% today, with a bullish technical signal and strong support at $44. The stock shows solid fundamentals with a P/E of 9.58, revenue of $21.11B in 2025, and consistent earnings beats. Recent news highlights AI partnerships with Google Cloud and OpenAI, positioning the company for growth in enterprise AI services.
The outlook is positive with a consensus price target of $63.45, implying significant upside. Risks include competitive pressures and macroeconomic softness affecting demand. Analyst sentiment is mixed but leans bullish, with 43% buy ratings. The stock presents a value opportunity given its low valuation multiples and strategic AI investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →
